LivaNova PLC (LIVN) Receives Average Rating of “Hold” from Brokerages
Shares of LivaNova PLC (NASDAQ:LIVN) have received an average rating of “Hold” from the six brokerages that are currently covering the firm. Five investment analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $62.50.
A number of research analysts have issued reports on the stock. Canaccord Genuity decreased their target price on shares of LivaNova PLC from $67.00 to $54.00 and set a “hold” rating on the stock in a research report on Thursday, November 3rd. WBB Securities restated a “hold” rating and set a $60.00 target price on shares of LivaNova PLC in a research report on Wednesday, August 31st. Finally, Piper Jaffray Cos. restated an “overweight” rating and set a $70.00 target price (up previously from $59.00) on shares of LivaNova PLC in a research report on Friday, August 5th.
COPYRIGHT VIOLATION WARNING: This piece of content was first published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another site, it was copied illegally and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2016/11/27/livanova-plc-livn-receives-average-rating-of-hold-from-brokerages.html.
In related news, major shareholder Two S.C.A. Equinox sold 25,408 shares of the stock in a transaction that occurred on Tuesday, September 13th. The shares were sold at an average price of $60.02, for a total transaction of $1,524,988.16. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 0.70% of the company’s stock.
Several hedge funds have recently bought and sold shares of LIVN. FIL Ltd raised its stake in LivaNova PLC by 54.5% in the second quarter. FIL Ltd now owns 2,410,140 shares of the company’s stock valued at $120,672,000 after buying an additional 849,925 shares in the last quarter. Columbia Wanger Asset Management LLC bought a new position in shares of LivaNova PLC during the second quarter valued at approximately $110,867,000. Price T Rowe Associates Inc. MD increased its position in shares of LivaNova PLC by 1.8% in the third quarter. Price T Rowe Associates Inc. MD now owns 2,055,688 shares of the company’s stock valued at $123,567,000 after buying an additional 35,379 shares during the last quarter. FMR LLC increased its position in shares of LivaNova PLC by 5.0% in the second quarter. FMR LLC now owns 1,608,618 shares of the company’s stock valued at $80,761,000 after buying an additional 75,952 shares during the last quarter. Finally, Franklin Resources Inc. increased its position in shares of LivaNova PLC by 4.6% in the second quarter. Franklin Resources Inc. now owns 1,418,212 shares of the company’s stock valued at $71,237,000 after buying an additional 62,076 shares during the last quarter. Institutional investors and hedge funds own 61.38% of the company’s stock.
LivaNova PLC (NASDAQ:LIVN) opened at 45.49 on Tuesday. LivaNova PLC has a 52-week low of $40.83 and a 52-week high of $63.21. The company’s market cap is $2.22 billion. The company has a 50-day moving average of $50.50 and a 200 day moving average of $53.50.
LivaNova PLC (NASDAQ:LIVN) last announced its earnings results on Wednesday, November 2nd. The company reported $0.78 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.75 by $0.03. LivaNova PLC had a negative net margin of 5.51% and a positive return on equity of 4.42%. The firm had revenue of $295.30 million for the quarter, compared to analyst estimates of $299.40 million. Equities research analysts predict that LivaNova PLC will post $3.00 EPS for the current year.
About LivaNova PLC
LivaNova PLC is a medical technology company. The Company operates through three segments: Cardiac Surgery, Cardiac Rhythm Management (CRM) and Neuromodulation. The Cardiac Surgery business unit is engaged in the development, production and sale of cardiovascular surgery products, including oxygenators, heart-lung machines, perfusion tubing systems and systems for autotransfusion and autologous blood washing.
Receive News & Stock Ratings for LivaNova PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova PLC and related stocks with our FREE daily email newsletter.